Beta Bionics projects $131M-$136M 2026 revenue and raises gross margin outlook to 57.5%-59.5% [Seeking Alpha]
Beta Bionics, Inc. (BBNX)
Company Research
Source: Seeking Alpha
"We're pleased to share with you all today our financial results for the first quarter as well as positive updates to our full year guidance for 2026." (President, CEO & Director Sean Saint) Fresh Stock Ideas, Every Day Quick Insights Beta Bionics raised its 2026 revenue guidance to $131-$136 million, pharmacy channel mix to 37%-39%, and gross margin to 57.5%-59.5%. Q1 performance was driven by 57% year-over-year net sales growth, higher pharmacy channel adoption, improved gross margins from increased production, and one-time tailwinds. Key risks include unpredictability in pharmacy reimbursement, one-time margin tailwinds that may not repeat, high sales/marketing costs, and unresolved FDA warning letter concerns. More Trending News
Show less
Read more
Impact Snapshot
Event Time:
BBNX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BBNX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BBNX alerts
High impacting Beta Bionics, Inc. news events
Weekly update
A roundup of the hottest topics
BBNX
News
- Beta Bionics (BBNX) was downgraded by <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a> from "sell (d-)" to "sell (e+)".MarketBeat
- Beta Bionics (BBNX) had its price target lowered by Leerink Partners from $25.00 to $24.00. They now have an "outperform" rating on the stock.MarketBeat
- Beta Bionics (BBNX) had its price target lowered by Stifel Nicolaus from $22.00 to $20.00. They now have a "buy" rating on the stock.MarketBeat
- Beta Bionics, Inc. (BBNX) Reports Q1 Loss, Misses Revenue Estimates [Yahoo! Finance]Yahoo! Finance
- Beta Bionics BBNX Q1 2026 Earnings Transcript [Globe and Mail, The (Toronto, Canada)]Globe and Mail, The
BBNX
Earnings
- 4/21/26 - Beat
BBNX
Sec Filings
- 4/21/26 - Form 10-Q
- 4/21/26 - Form 8-K
- 4/10/26 - Form ARS
- BBNX's page on the SEC website